SCANCELL HLDGS ORD 0.1P (SCLP.L, LSE, LSE:SCLP)

SCLP Share PerformanceMore

52 week high47.000 09/12/13
52 week low23.930 15/11/13
52 week change -0.250 (-0.72%)
4 week volume2,857,501 02/08/14

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Scancell Holdings - Synergy of SCIB1 with checkpoint inhibitors

Synergy of SCIB1 with checkpoint inhibitors

Miscellaneous medium priority announcements

Director/PDMR Shareholding

Notification of issuers, persons discharging managerial responsibilities and their connected persons in respect of transactions conducted in their own account in shares of the issuer

Scancell Holdings - SCIB1 Phase 1/2 clinical trial results presented at ASCO and DNA ImmunoBody patent granted in United States

DNA ImmunoBody Patent Granted in United States

Miscellaneous medium priority announcements

Scancell updates on Phase 1/2 trial of SCIB1 in melanoma

Scancell Holdings confirms further encouraging results from its on-going Phase 12 clinical trial in patients with Stage IIIIV...

Update on Phase 1/2 trial of SCIB1 in melanoma

Miscellaneous medium priority announcements

Presents latest SCIB1 data at ASCO

Miscellaneous medium priority announcements